These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 14744396

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
    Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clò V, Casolari B.
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
    [Abstract] [Full Text] [Related]

  • 4. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K.
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [Abstract] [Full Text] [Related]

  • 5. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
    Jabr FI.
    Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
    [Abstract] [Full Text] [Related]

  • 6. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.
    J Immunother; 2009 Nov; 32(6):622-31. PubMed ID: 19483647
    [Abstract] [Full Text] [Related]

  • 7. [Resistance to rituximab and CD20 mutation].
    Terui Y, Hatake K.
    Nihon Rinsho; 2007 Jan 28; 65 Suppl 1():416-23. PubMed ID: 17474440
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
    Kollmar O, Becker S, Schilling MK, Maurer CA.
    Transplantation; 2002 Feb 27; 73(4):669-70. PubMed ID: 11889454
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C, DeNardo G, Tobin E, DeNardo S.
    Cancer Biother Radiopharm; 2004 Oct 27; 19(5):545-61. PubMed ID: 15650447
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection.
    Spina M, Sparano JA, Jaeger U, Rossi G, Tirelli U.
    AIDS; 2003 Jan 03; 17(1):137-8. PubMed ID: 12478085
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.